A Modified Thromboelastographic Method for Monitoring c7E3 Fab in Heparinized Patients

This publication has 17 references indexed in Scilit:

• Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors
  Journal of the American College of Cardiology, 1995
• Bleeding Complications With the Chimeric Antibody to Platelet Glycoprotein IIb/IIIa Integrin in Patients Undergoing Percutaneous Coronary Intervention
  Circulation, 1995
• Reductions in Platelet Force Development by Cardiopulmonary Bypass Are Associated with Hemorrhage
  Anesthesia & Analgesia, 1995
• At high heparin concentrations, protamine concentrations which reverse heparin anticoagulant effects are insufficient to reverse heparin anti-platelet effects
  Thrombosis Research, 1994
• Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty
  New England Journal of Medicine, 1994
• Flow cytometric observations on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein IIb-IIIa
  Blood Coagulation & Fibrinolysis, 1993
• Measurement of Platelet-Mediated Force Development During Plasma Clot Formation
  The Lancet Healthy Longevity, 1991
• Monoclonal Antibodies to Platelet Glycoprotein IIb/IIIa as Antithrombotic Agentsa
  Annals of the New York Academy of Sciences, 1991
• Thrombelastography of blood from subjects with chronic renal failure
  Thrombosis Research, 1987
• A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa.
  Journal of Clinical Investigation, 1983